Related Experiment Video
Updated: Jul 11, 2025

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
CYP2C19 Polymorphisms and Clinical Outcomes Following Percutaneous Coronary Intervention (PCI) in the Million
Catherine Chanfreau-Coffinier1, Kevin A Friede2, Mary E Plomondon3
1VA Salt Lake City Heath Care System, Salt Lake City, UT.
CYP2C19 loss-of-function alleles increase MACE risk in acute coronary syndrome patients after PCI. However, CYP2C19 genotype does not impact MACE risk in stable ischemic heart disease patients treated with clopidogrel.
Area of Science:
- Pharmacogenomics
- Cardiovascular Medicine
- Interventional Cardiology
Background:
- CYP2C19 loss-of-function (LOF) alleles are known to reduce clopidogrel's antiplatelet efficacy post-percutaneous coronary intervention (PCI) in acute coronary syndrome (ACS) patients.
- The clinical significance of CYP2C19 genotype in stable ischemic heart disease (SIHD) patients undergoing PCI remains less understood.
Conclusions:
- CYP2C19 LOF carriers with ACS treated with clopidogrel post-PCI face a numerically increased risk of MACE.
- CYP2C19 genotype does not appear to be associated with MACE risk in SIHD patients undergoing PCI and treated with clopidogrel.
More Related Videos
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
10:03Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Related Concept Videos
Coronary Artery Disease V: Interprofessional Care
Cardiomyopathy V: Interprofessional Care
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Cardiac Catheterization I: Pre-Procedure Overview
Cardiomyopathy II: Dilated Cardiomyopathy